Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
CAMBRIDGE, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases, today announced the appointments of Amy Rock, Ph.D., as Chief Regulatory and Quality Officer and Dae Gon Ha, Ph.D., as Senior Vice President, Corporate Development. The Company also announced that Timothy Keutzer, Chief Operating Officer, will retire from Spero effective December 31, 2026.
Covered in this story
Call it yourself
No calls on $SPRO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Spero Therapeutics →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.